SCHEMBL8444529

SCHEMBL8444529

COc1ccccc1N1CCN(CC(C(=O)N2CCC2)c2ccccc2)CC1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 4/20 0.75
HTR1D P28221 1/20 0.75
HTR2B P41595 1/20 0.75
ALDH1A1 P00352 4/20 0.71
LMNA P02545 2/20 0.71
KDM4E B2RXH2 2/20 0.70
CYP1A2 P05177 1/20 0.70
CYP3A4 P08684 1/20 0.70
CYP2D6 P10635 1/20 0.70
ALOX15 P16050 1/20 0.70
HSD17B10 Q99714 1/20 0.70
TDP1 Q9NUW8 1/20 0.60
DRD2 P14416 2/20 0.56
DRD4 P21917 1/20 0.56
DRD3 P35462 1/20 0.56
IGF1R P08069 1/20 0.55
HTR2A P28223 1/20 0.54
RECQL P46063 1/20 0.53
ADRB2 P07550 1/20 0.53
ADRB1 P08588 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8442968 0.98 HTR1A (0.78) HTR1AHTR1DHTR2BALDH1A1LMNA
SCHEMBL8442654 0.97 HTR1A (0.80) HTR1AHTR1DHTR2BALDH1A1LMNA
SCHEMBL9004457 0.97 HTR1A (0.80) HTR1AHTR1DHTR2BALDH1A1LMNA
SCHEMBL8442711 0.90 ALDH1A1 (0.67) HTR1AHTR1DHTR2BALDH1A1LMNA
SCHEMBL8442538 0.88 HTR1A (0.76) HTR1AHTR1DHTR2BALDH1A1LMNA
SCHEMBL8442467 0.87 HTR1A (0.78) HTR1AHTR1DHTR2BALDH1A1LMNA
SCHEMBL8443682 0.86 HTR1A (0.72) HTR1AHTR1DHTR2BALDH1A1LMNA
SCHEMBL6546383 0.86 HTR1A (1.00) HTR1AHTR1DHTR2BALDH1A1LMNA
SCHEMBL8065712 0.86 HTR1A (1.00) HTR1AHTR1DHTR2BALDH1A1LMNA
SCHEMBL8445488 0.85 HTR1A (0.71) HTR1AHTR1DHTR2BALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0395312-B1 Piperazine derivatives WYETH JOHN & BROTHER LTD (GB) 1999-05-12 EP claimed
US-5364849-A Treatment of anxiety JOHN WYETH & BROTHER, LIMITED (GB) 1994-11-15 US claimed
EP-0395312-A2 Piperazine derivatives JOHN WYETH & BROTHER LIMITED (GB) 1990-10-31 EP claimed
EP-0395312-B1 Piperazine derivatives WYETH JOHN & BROTHER LTD (GB) 1999-05-12 EP disclosed
US-5541326-A PHARMACEUTICAL COMPOSITION USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS JOHN WYETH & BROTHER, LIMITED (GB) 1996-07-30 US disclosed
US-5420278-A ω-(4-aryl or heteroarylpiperazine-1-yl)-2-aryl or aralkyl-propanoic or butanoic acids JOHN WYETH & BROTHER, LIMITED (GB) 1995-05-30 US disclosed
US-5382583-A Hydroxytryptamine antagonists JOHN WYETH & BROTHER, LIMITED (GB) 1995-01-17 US disclosed
US-5364849-A Treatment of anxiety JOHN WYETH & BROTHER, LIMITED (GB) 1994-11-15 US disclosed
US-5340812-A Antiserotonin. anxiolytic agents JOHN WYETH & BROTHER, LIMITED (GB) 1994-08-23 US disclosed
EP-0395312-A2 Piperazine derivatives JOHN WYETH & BROTHER LIMITED (GB) 1990-10-31 EP disclosed